408 results on '"Bria, Emilio"'
Search Results
2. Implementation of Artificial Intelligence in Personalized Prognostic Assessment of Lung Cancer: A Narrative Review
3. Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK‐positive advanced nonsmall cell lung cancer
4. Accessible Machine Learning and Deep Learning Models Predict Response and Survival in Early Stage Hormone Receptor-Positive/HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
5. Response to first-line pembrolizumab in metastatic KRAS-mutated non-small-cell lung cancer
6. Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial
7. Characterization of two transcriptomic subtypes of marker-null large cell carcinoma of the lung suggests different origin and potential new therapeutic perspectives
8. Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program
9. Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study
10. Extension of the SPIRIT 2013 Statement for Factorial Randomized Trials—A Step Toward Transparency and the Curse of Interaction
11. Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies
12. Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer
13. Correction: Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study
14. Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer—Immun-HER trial (GOIRC-01-2016)
15. Bronchoscopically-visible massive central airway cancer cavitation is associated with metastatic disease, lack of actionable mutations and poor prognosis: a case series
16. Adjuvant Targeted Therapy in Solid Cancers: Pioneers and New Glories
17. Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients
18. Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC)
19. Maintenance Strategies After Anti-EGFR-based Induction in Metastatic Colorectal Cancer: A Systematic Review and Bayesian Network Meta-analysis
20. RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion
21. Supplementary Data S3 from Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages
22. Supplementary Data S1 from Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages
23. Data from Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages
24. Supplementary Data S1 from Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages
25. Supplementary Data S2 from Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages
26. Supplementary Data from Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages
27. Supplementary Data S2 from Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages
28. Supplementary Data S3 from Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages
29. Supplementary Data from Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages
30. Seize the Opportunity With Small Tissue Samples: The Tailor Teaches!
31. Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors
32. Supplementary methods from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
33. Table S2 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
34. Supplementary methods from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
35. Table S3 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
36. Table S1 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
37. Figure S1 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
38. Table S3 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
39. Figure S1 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
40. Figure S2 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
41. Legends of supplementary figure 1 and 2 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
42. Table S1 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
43. Legends of supplementary figure 1 and 2 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
44. Table S2 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
45. Figure S2 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
46. Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings
47. Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response
48. Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
49. Salvage surgery after first-line Alectinib for locally-advanced/metastatic ALK-rearranged NSCLC: pathological response and peri-operative results
50. Abstract GS3-01: GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.